aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 411,800 shares, a decrease of 5.9% from the August 31st total of 437,400 shares. Based on an average daily volume of 256,600 shares, the days-to-cover ratio […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Free Report) – Equities researchers at HC Wainwright boosted their FY2025 earnings estimates for aTyr Pharma in a report released on Thursday, September 21st. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($0.93) per share for the year, up from their prior forecast of ($0.99). […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price […]
StockNews.com assumed coverage on shares of aTyr Pharma (NASDAQ:LIFE – Free Report) in a report released on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Several other research analysts have also recently commented on LIFE. Oppenheimer cut aTyr Pharma from an outperform rating to a market perform rating in a research […]